Archive: March 25, 2020

Saiba AG Shows encouraging preclinical data for its COVID-19 VLP-based vaccine

(PFÄFFIKON), March 25, 2020 — Saiba AG, , has developed a proprietary platform technology based on immunologically optimized virus-like particles. This platform technology has now enabled scientists to establish preclinical proof-of-concept for a vaccine against COVID-19. The vaccine candidate has been able to induce in test animals high levels of antibodies that neutralize the …

Read More